Md., April 26 /PRNewswire-FirstCall/ -- Protiveris
Inc., a bio- nanotechnology company commercializing
nano-mechanical technologies to facilitate biomolecular
research, today announced that it has successfully
completed installation of its VeriScan(TM) 3000
Biosensor System at the Lombardi Comprehensive
Cancer Center at Georgetown University. Dr. Andrew
Quong, who leads the Center's Division of Nanotechnology
and Integrative Cancer Biology in the Department
of Oncology, will direct a collaborative effort
to explore the use of nanotechnologies in cancer
research using Protiveris's microcantilever-based
represents a significant milestone for Protiveris
as it is the first VeriScan System collaboration
with specific clinical cancer research applications," commented
Robert Menzi, Chief Operating Officer at Protiveris. "Dr.
Quong and his team at Lombardi are uniquely qualified
to develop new approaches using our nano-technology
products. Dr Quong understands the full range of
scientific and technological requirements -- from
engineering and physics to chemistry and biology
-- necessary to develop successful and innovative
approaches to cancer research."
"This as a unique
opportunity to bring the latest advances in the emerging
field of nanotechnology to cancer diagnosis and therapeutic
stratification," added Dr Quong. "The Protiveris
VeriScan Biosensor System affords us the potential
to perform highly sensitive multiplexed assays for
both laboratory and clinical use on a stable, well
engineered platform." The VeriScan 3000 protein
biochip and optical reader utilize arrays of microcantilevers
with customizable surfaces to measure, label-free
and in real-time, multiplex and distinct protein,
antibody, antigen, or DNA biomolecular interactions.
Protiveris is currently installing this system
in forward-looking research facilities in the United
States and Europe. About Protiveris, Inc. Protiveris
is committed to establishing the standard of performance
for proteomic research tools.
VeriScan(TM) 3000 bench-top biochip system measures
and analyzes biomolecular and chemical interactions
to enable more efficient and accurate research
outcomes. The biochip utilizes arrays of microcantilevers
with customizable surfaces to detect interactions
between proteins, antibodies, antigens, or DNA.
This label-free system provides researchers with
the ability to create high content assays that
deliver real time data. More information about
Protiveris, their technology, products, and services
can be found at the company's web site at http://www.protiveris.com .
the Lombardi Comprehensive Cancer Center Established
in 1970, the Lombardi Comprehensive Cancer Center
is named for the legendary Green Bay Packers and
Washington Redskins coach Vince Lombardi, who was
treated for cancer at Georgetown University Hospital.
What began as a small clinic grew over the years
to become a state-of-the-art cancer center. In
1990, the Lombardi Center won the designation of "Comprehensive
Cancer Center" from the National Cancer Institute
(NCI). To obtain this designation, a center must
meet strict research, clinical trials and community
outreach criteria. In 2003, Lombardi's comprehensive
cancer center status was renewed by the NCI.
Lombardi's internationally renowned clinical
team offers the latest treatments for virtually
every type of cancer, with a particular emphasis
in solid tumors and adult and pediatric hematologic
information about Lombardi Comprehensive Cancer
Center can be found at http://lombardi.georgetown.edu .
SOURCE Protiveris Inc.
Web Site: http://www.protiveris.com